Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew A Somogyi

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Internal Medicine Journal|April 10, 2020
Pharmacogenetics of statin intoleranceGraeme Suthers, Andrew A Somogyi
Australian Prescriber|August 12, 2017
Genomic testing as a tool to optimise drug therapyAndrew A Somogyi, Elizabeth Phillips
European Journal of Pharmacology|October 24, 2002
Diacetylmorphine degradation to 6-monoacetylmorphine and morphine in cell culture: implications for in vitro studiesMark R Hutchinson, Andrew A Somogyi
British Journal of Clinical Pharmacology|November 19, 2024
Pharmacogenomics in 2023: Big studies, big results, big implications, big responsibilities: EditorialAnn K Daly, Andrew A Somogyi
International Immunopharmacology|August 17, 2005
Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioidsMark R Hutchinson, Andrew A Somogyi
European Journal of Pharmacology|June 24, 2004
Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferationMark R Hutchinson, Andrew A Somogyi
International Immunopharmacology|September 8, 2004
(S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(--)-methadoneMark R Hutchinson, Andrew A Somogyi
European Journal of Clinical Pharmacology|October 30, 2008
Role of active metabolites in the use of opioidsJanet K Coller, Lona L Christrup, Andrew A Somogyi
Addiction Biology|May 15, 2002
In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexoneSusan J Porter, Andrew A Somogyi, Jason M White
Addiction (Abingdon, England)|September 3, 2011
The effect of methadone on emotional reactivitySteven M Savvas, Andrew A Somogyi, Jason M White
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Internal Medicine Journal|April 10, 2020
Pharmacogenetics of statin intoleranceGraeme Suthers, Andrew A Somogyi
Australian Prescriber|August 12, 2017
Genomic testing as a tool to optimise drug therapyAndrew A Somogyi, Elizabeth Phillips
European Journal of Pharmacology|October 24, 2002
Diacetylmorphine degradation to 6-monoacetylmorphine and morphine in cell culture: implications for in vitro studiesMark R Hutchinson, Andrew A Somogyi
British Journal of Clinical Pharmacology|November 19, 2024
Pharmacogenomics in 2023: Big studies, big results, big implications, big responsibilities: EditorialAnn K Daly, Andrew A Somogyi
International Immunopharmacology|August 17, 2005
Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioidsMark R Hutchinson, Andrew A Somogyi
European Journal of Pharmacology|June 24, 2004
Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferationMark R Hutchinson, Andrew A Somogyi
International Immunopharmacology|September 8, 2004
(S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(--)-methadoneMark R Hutchinson, Andrew A Somogyi
European Journal of Clinical Pharmacology|October 30, 2008
Role of active metabolites in the use of opioidsJanet K Coller, Lona L Christrup, Andrew A Somogyi
Addiction Biology|May 15, 2002
In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexoneSusan J Porter, Andrew A Somogyi, Jason M White
Addiction (Abingdon, England)|September 3, 2011
The effect of methadone on emotional reactivitySteven M Savvas, Andrew A Somogyi, Jason M White
Pageof 16